VectorBuilder, a specialist in genetic engineering based in China, has entered into a strategic partnership with Minaris Regenerative Medicine, a cell and gene therapy (CGT) Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Japan-headquartered Showa Denko Materials Co., Ltd. This collaboration aims to integrate VectorBuilder’s superior R&D and production capabilities in GMP level carriers with Minaris’ extensive experience in CGT production, thereby offering customers more comprehensive and efficient solutions.
The partnership will see both companies capitalize on their respective expertise to streamline and enhance the production process of in vitro gene therapy drugs, such as chimeric antigen receptor T cells (CAR-T). This collaboration is poised to provide innovative support for the development of gene therapies, further advancing the field and benefiting customers with cutting-edge solutions.- Flcube.com
